Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2013

Open Access 01-12-2013 | Research

Dose to organs at risk in the upper abdomen in patients treated with extended fields by helical tomotherapy: a dosimetric and clinical preliminary study

Authors: Sara Bresciani, Elisabetta Garibaldi, Gabriella Cattari, Angelo Maggio, Amalia Di Dia, Elena Delmastro, Domenico Gabriele, Michele Stasi, Pietro Gabriele

Published in: Radiation Oncology | Issue 1/2013

Login to get access

Abstract

Background

The aim of this work was to determine the technical feasibility and safety of extended-field radiotherapy (EF), performed by Helical TomoTherapy, in patients with positive pelvic and/or para-aortic nodes. Dosimetric data were collected and acute and sub-acute toxicities of the upper abdominal organs at risk (OAR) were evaluated.

Methods

Twenty-nine patients suitable for EF irradiation for local disease and/or nodal disease in the pelvic or para-aortic area were treated. The prescription dose was 50.4/54 Gy (1.7-1.8 Gy/fraction) for prophylactic lymph nodes (N-) and 60–70.5 Gy (2–2.35 Gy/fraction) for clinically evident gross disease (N+). Modulation factor (MF), pitch and field width (FW) were chosen to optimize dose distribution and treatment duration. Dose values of PTVs and OAR were analysed. The length of the treatment field, the N + and N- volumes, and treatment duration were reported. To evaluate the safety of treatment, haematological, hepatic, renal and pancreatic functions were assessed before, during and after treatment. The median follow-up time was 17.6 months (range: 6–22 months).

Results

The treatment was well tolerated and all patients but one completed treatment without interruption. Four of the 29 patients experienced G3 haematological acute toxicity (13.8%), but no patient experienced sub-acute grade G3 toxicity. Ten patients experienced G1 and three G2 acute gastrointestinal toxicity (nausea). No sub-acute gastrointestinal or renal toxicity was observed. Only one (3.7%) patient had a persistent slight increase of pancreatic enzymes and two (7.4%) patients a slight increase of hepatic enzymes six months after radiotherapy (G1 toxicity).

Conclusions

With our treatment design and dose regimen, we found that EF treatment by TomoTherapy could be safely and effectively delivered with minimal acute and sub-acute toxicities in the upper abdomen area.
Appendix
Available only for authorised users
Literature
1.
Du XL, Sheng XG, Jiang T, et al.: Intensity-modulated radiation therapy versus para-aortic field radiotherapy to treat para-aortic lymph node metastasis in cervical cancer: prospective study. Croat Med J 2010,51(3):229-36. 10.3325/cmj.2010.51.229CrossRefPubMedPubMedCentral
2.
Silberstein AB, Anon BS, Alexander LL: Para-aortic lymph node irradiation in cervical carcinoma. Radiology 1970, 95: 181-184.CrossRefPubMed
3.
Fletcher GH, Rutledge FN: Extended field technique in the management of the cancers of the uterine cervix. Am J Roentgenol 1972, 114: 116-122.
4.
Zunino S, Rosato O, Lucino S, et al.: Anatomic study of the pelvis in carcinoma of the uterine cervix as related to the box technique. Int J Radiat Oncol Biol Phys 1999, 44: 53-9. 10.1016/S0360-3016(98)00538-0CrossRefPubMed
5.
Sood BM, Gorla GR, Garg M, et al.: Extended-field radiotherapy and high-dose-rate brachytherapy in carcinoma of the uterine cervix: clinical experience with and without concomitant chemotherapy. Cancer 2003, 97: 1781-1788. 10.1002/cncr.11248CrossRefPubMed
6.
Salama JK, Mundt AJ, Roeske J, et al.: Preliminary outcome and toxicity report of extended-field, intensity-modulated radiation therapy for gynecologic malignancies. Int J Radiat Oncol Biol Phys 2006, 65: 1170-1176. 10.1016/j.ijrobp.2006.02.041CrossRefPubMed
7.
Portelance L, Chao KS, Grigsby PW, et al.: Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. Int J Radiat Oncol Biol Phys 2001, 51: 261-266.CrossRefPubMed
8.
Ahmed RS, Kim RY, Duan J, et al.: IMRT dose escalation for positive para-aortic lymph nodes in patients with locally advanced cervical cancer while reducing dose to bone marrow and other organs at risk. Int J Radiat Oncol Biol Phys 2004,60(2):505-12. 10.1016/j.ijrobp.2004.03.035CrossRefPubMed
9.
Poorvu PD, Sadow CA, Townamchai K, et al.: Duodenal and other gastrointestinal toxicity in cervical and endometrial cancer treated with extended-field intensity modulated radiation therapy to paraaortic lymph nodes. Int J Radiat Oncol Biol Phys 2012. article in press
10.
Marnitz S, Köhler C, Burova E, et al.: Helical tomotherapy with simultaneous integrated boost after laparoscopic staging in patients with cervical cancer: analysis of feasibility and early toxicity. Int J Radiat Oncol Biol Phys 2012,82(2):e137-43. 10.1016/j.ijrobp.2010.10.066CrossRefPubMed
11.
Lian J, Mackenzie M, Joseph K, et al.: Assessment of extended field radiotherapy for stage IIIC endometrial cancer using three dimensional conformal radiotherapy, intensity-modulated radiotherapy and helical tomotherapy. Int J Radiat Oncol Biol Phys 2008, 70: 935-943. 10.1016/j.ijrobp.2007.10.021CrossRefPubMed
12.
Hsieh CH, Wie MC, Lee HL, et al.: Whole pelvic helical tomotherapy for locally advanced cervical cancer: technical implementation of IMRT with helical tomotherapy. Radiat Oncol 2009, 4: 62. 10.1186/1748-717X-4-62CrossRefPubMedPubMedCentral
13.
Jackson A, Marks LB, Bentzen SM, et al.: The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. Int J Radiat Oncol Biol Phys 2010,76(3):S155-60. 10.1016/j.ijrobp.2009.08.074CrossRefPubMedPubMedCentral
14.
ICRU: International commission on radiation units and measurements (ICRU): prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50). Bethesda, MD, USA: ICRU Report 62; 1999.
15.
ICRU: International commission on radiation units and measurements (ICRU): prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT), ICRU Report, 83. Oxford: Oxford University press; 2010. Volume 10 No 1
16.
Hälg RA, Besserer J, Schneider U: Systematic measurements of whole-body dose distributions for various treatment machines and delivery techniques in radiation therapy. Med Phys 2012,39(12):7662-7676. 10.1118/1.4767773CrossRefPubMed
17.
Rotman M, Pajak TF, Choi K, et al.: Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas: ten-year treatment results of RTOG 79–20. JAMA 1995, 274: 387-393. 10.1001/jama.1995.03530050035029CrossRefPubMed
18.
Kidd EA, Siegel BA, Dehdashti F, et al.: Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2010, 77: 1085-1091. 10.1016/j.ijrobp.2009.06.041CrossRefPubMed
Metadata
Title
Dose to organs at risk in the upper abdomen in patients treated with extended fields by helical tomotherapy: a dosimetric and clinical preliminary study
Authors
Sara Bresciani
Elisabetta Garibaldi
Gabriella Cattari
Angelo Maggio
Amalia Di Dia
Elena Delmastro
Domenico Gabriele
Michele Stasi
Pietro Gabriele
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2013
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-8-247

Other articles of this Issue 1/2013

Radiation Oncology 1/2013 Go to the issue

Research

Patterns of radiotherapy practice for biliary tract cancer in Japan: results of the Japanese radiation oncology study group (JROSG) survey

Research

Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A

Research

Increased radiosensitivity and radiothermosensitivity of human pancreatic MIAPaCa-2 and U251 glioblastoma cell lines treated with the novel Hsp90 inhibitorNVP-HSP990

Research

Hepatic arterial phase and portal venous phase computed tomography for dose calculation of stereotactic body radiation therapy plans in liver cancer: a dosimetric comparison study

Research

Phase II randomized, double-blind, placebo-controlled study of whole-brain irradiation with concomitant chloroquine for brain metastases

Research

Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results